Kwak JH - Search Results

1

Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats.

Kim DK, Chung SY, Kwak JH, Kim MS, Staatz CE, Lee HS, Baek IH. Kim DK, et al. Among authors: kwak jh. Xenobiotica. 2021 Feb;51(2):194-201. doi: 10.1080/00498254.2020.1822565. Epub 2020 Sep 22. Xenobiotica. 2021. PMID: 32915088

2

Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.

Ha DK, Kim MJ, Han N, Kwak JH, Baek IH. Ha DK, et al. Among authors: kwak jh. Clin Drug Investig. 2021 Feb;41(2):119-132. doi: 10.1007/s40261-020-00997-1. Epub 2021 Jan 11. Clin Drug Investig. 2021. PMID: 33426614

3

Oral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in rats.

Kwak JH, Kim Y, Staatz CE, Baek IH. Kwak JH, et al. Xenobiotica. 2021 Jul;51(7):811-817. doi: 10.1080/00498254.2021.1925774. Epub 2021 May 17. Xenobiotica. 2021. PMID: 33949288

4

Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.

Jang H, Han N, Staatz CE, Kwak JH, Baek IH. Jang H, et al. Among authors: kwak jh. Clin Res Hepatol Gastroenterol. 2023 Dec;47(10):102227. doi: 10.1016/j.clinre.2023.102227. Epub 2023 Oct 24. Clin Res Hepatol Gastroenterol. 2023. PMID: 37884091 Review.

5

Synthesis and anti-platelet activity of obovatol derivatives.

Kwak JH, Lee S, Park ES, In JK, Song J, Kim YJ, Choi NS, Lee H, Yun YP, Hong JT, Kwak YS, Min KH, Jung JK. Kwak JH, et al. Among authors: kwak ys. Arch Pharm Res. 2011 Jul;34(7):1107-12. doi: 10.1007/s12272-011-0708-9. Epub 2011 Aug 3. Arch Pharm Res. 2011. PMID: 21811917

6

Nuclear factor-kappa B inhibitors; a patent review (2006-2010).

Kwak JH, Jung JK, Lee H. Kwak JH, et al. Expert Opin Ther Pat. 2011 Dec;21(12):1897-910. doi: 10.1517/13543776.2011.638285. Expert Opin Ther Pat. 2011. PMID: 22098320 Review.

7

A novel synthetic compound MCAP suppresses LPS-induced murine microglial activation in vitro via inhibiting NF-kB and p38 MAPK pathways.

Kim BW, More SV, Yun YS, Ko HM, Kwak JH, Lee H, Suk K, Kim IS, Choi DK. Kim BW, et al. Among authors: kwak jh. Acta Pharmacol Sin. 2016 Mar;37(3):334-43. doi: 10.1038/aps.2015.138. Epub 2016 Feb 1. Acta Pharmacol Sin. 2016. PMID: 26838070 Free PMC article.

8

Synthesis and Biological Evaluation of (S)-2-(Substituted arylmethyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide Analogs and Their Synergistic Effect against PTEN-Deficient MDA-MB-468 Cells.

Kwon YM, Kim SH, Jung YS, Kwak JH. Kwon YM, et al. Among authors: kwak jh. Pharmaceuticals (Basel). 2021 Sep 25;14(10):974. doi: 10.3390/ph14100974. Pharmaceuticals (Basel). 2021. PMID: 34681198 Free PMC article.

9

Synthesis and nuclear factor-kappaB inhibitory activities of 6- or 7-methylchroman-2-carboxylic acid N-(substituted) phenylamides.

Kwak JH, Won SW, Kim TJ, Yi W, Choi EH, Kim SC, Park H, Roh E, Jung JK, Hwang BY, Hong JT, Kim Y, Cho J, Lee H. Kwak JH, et al. Arch Pharm Res. 2009 Feb;32(2):167-75. doi: 10.1007/s12272-009-1131-3. Epub 2009 Mar 13. Arch Pharm Res. 2009. PMID: 19280144

10

Design and synthesis of 2,3-dihydro- and 5-chloro-2,3-dihydro-naphtho-[1,2-b]furan-2-carboxylic acid N-(substitutedphenyl)amide analogs and their biological activities as inhibitors of NF-κB activity and anticancer agents.

Choi M, Jo H, Kim D, Yun J, Kang JS, Kim Y, Jung JK, Hong JT, Cho J, Kwak JH, Lee H. Choi M, et al. Among authors: kwak jh. Arch Pharm Res. 2016 May;39(5):618-30. doi: 10.1007/s12272-016-0737-5. Epub 2016 Mar 28. Arch Pharm Res. 2016. PMID: 27021311

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

509 results

Search Page